Biogen Inc. (NASDAQ: BIIB) and Sage Therapeutics, Inc. (NASDAQ: SAGE) communicated that they are partnering together and will be combining their efforts to develop and commercialize SAGE-324 for neurological disorders like tremors and SAGE-217 i.e. Zuranolone for Postpartum Depression (PPD), Major Depressive Disorders (MDD) and other similar psychiatric conditions. Both the companies have signed a licensing agreement and are tirelessly working day and night to come up with the best of the best.
Approximately 17M U.S citizens are diagnosed with such diseases and have limited access to medical facilities. However, experts believe that the discovery of this therapy will aid in transforming the way mental disorders are looked at and treated and may have the potential to change people’s perspectives on the use of antidepressants.
After undergoing several clinical trials it was observed that the drug provides lasting benefits even after appropriate amounts of dosage have been administered and is said to work wonders. Currently, it is in Phase 3 of its development and it could very well turn into a monumental discovery and play a pivotal role in improving the quality of life of many Americans.
Both companies will share the loss as well as profit and if Sage manages to accomplish specified milestones it will be entitled to receive US$1.6B.